Rare & Genetic · Clinical trials
AL Amyloidosis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About al amyloidosis — and why its trials are hard
AL (light-chain) amyloidosis is a rare plasma-cell disorder in which a clonal population produces misfolded immunoglobulin light chains that deposit as amyloid fibrils in organs, most dangerously the heart and kidneys. Cardiac involvement drives prognosis, and Mayo staging (based on cardiac biomarkers NT-proBNP and troponin plus the difference in involved/uninvolved free light chains) stratifies risk. Treatment targets the underlying plasma-cell clone to halt light-chain production, with hematologic response depth (complete response and free light-chain normalization) correlating with organ recovery and survival. Historically bortezomib-based regimens (CyBorD) were standard, but in January 2021 the addition of the anti-CD38 antibody daratumumab (subcutaneous, with hyaluronidase) to bortezomib-cyclophosphamide-dexamethasone became the first FDA-approved regimen specifically for newly diagnosed AL amyloidosis, based on the ANDROMEDA trial. A parallel strategy of directly clearing existing amyloid deposits with antibodies (e.g., birtamimab) has repeatedly failed in Phase 3, underscoring the difficulty of reversing established organ deposits. Unmet need remains high for advanced-stage (Mayo IV) patients with poor short-term survival.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| daratumumab and hyaluronidase (with bortezomib-cyclophosphamide-dexamethasone) (Darzalex Faspro (+ CyBorD/VCd)) | 2021 | Newly diagnosed AL amyloidosis (first FDA-approved regimen for the indication) | ANDROMEDA (Phase 3, dara-VCd vs VCd) | Hematologic complete response (hemCR) | hemCR ~53% with dara-VCd vs ~18% with VCd (p<0.001); improved organ response and survival-free outcomes |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in al amyloidosis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| birtamimab — VITAL (Phase 3, birtamimab + standard of care vs placebo + SOC) | Stopped for futility; did not meet the primary composite endpoint of all-cause mortality plus cardiovascular hospitalization | Anti-fibril antibody targeting deposited amyloid rather than the plasma-cell clone; a post hoc survival signal in Mayo stage IV patients prompted the confirmatory AFFIRM-AL trial, which subsequently also did not meet its primary endpoint (2025) |
Choosing the right endpoint
Primary endpoints that matter in al amyloidosis trials
- Hematologic complete response (hemCR) — Deepest suppression of the amyloidogenic light-chain clone; the ANDROMEDA primary endpoint and strongest predictor of organ recovery
- Difference in free light chains (dFLC) response — Reduction/normalization of the involved-minus-uninvolved free light-chain gap tracks clonal control
- Cardiac response (NT-proBNP-based) — Reflects organ improvement; cardiac involvement dominates prognosis
- Overall survival / major organ deterioration-free survival — Definitive outcomes, especially critical in advanced Mayo stage IV disease
How iNGENū runs al amyloidosis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
AL Amyloidosis clinical trials — FAQs
What is the first approved regimen for AL amyloidosis?
Why do therapies target plasma cells rather than the amyloid deposits?
What does hematologic complete response mean?
Ready to discuss your al amyloidosis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal